Novo Nordisk Breaks Ground on New Insulin Manufacturing Facility
Novo Nordisk is investing 2.1 billion Danish kroner ($306 million) in a new 10,300-square-meter facility in HillerÃ¸d, Denmark. The facility will produce medicines for the treatment of diabetes and obesity. The company held a groundbreaking ceremony marking the start of construction.
The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in HillerÃ¸d, where Novo Nordisk already employs 1,900 people.
Established in 1992, the HillerÃ¸d site covers an area of about 1,650,000 square meters, of which 90,000 square meters is used for production, research, and development. The site houses a facility for device R&D and three production facilities: one for molding and pre-assembly of components; one for filling, assembly, and packaging of diabetes finished products; and one for the production of active pharmaceutical ingredients for hemophilia products. Novo Nordisk has made ongoing investments in the site of approximately 350 million kroner ($51 million) per year on average.
Source: Novo Nordisk